PHG — Koninklijke Philips N.V.

Summary of Royal Philips Q4 and Full Year 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Performance:

  • Order intake increased by 7% year-on-year.
  • Comparable sales growth of 7%, broad-based across all segments.
  • Adjusted EBITDA margin improved by 160 basis points to 15.1%.
  • Net income rose to EUR 397 million, reflecting improved operations and lower tax charges.
  • Adjusted diluted earnings per share increased by 20% to EUR 0.60.
  • Free cash flow for Q4 was EUR 1.2 billion, down EUR 85 million year-over-year due to a tough comparison base.

• Full Year 2025 Performance:

  • Order intake grew 6% for the year.
  • Comparable sales growth was 2.3%, in line with expectations.
  • Adjusted EBITDA margin increased by 80 basis points to 12.3%.
  • Total free cash flow reached EUR 512 million.

2. Strategic Updates and Business Highlights

• Business Segments:

  • Diagnosis & Treatment (D&T): Comparable sales growth of 4% in Q4, with strong performance in Image-Guided Therapy (double-digit growth). Adjusted EBITDA margin declined slightly to 11.8%.
  • Connected Care: Achieved 7% sales growth in Q4, with a margin expansion to 16.5%. Strong demand for monitoring and enterprise informatics solutions, particularly in North America.
  • Personal Health: Sales grew 14% in Q4, with a margin of 23%, driven by strong demand for premium products and effective commercial execution.

• Innovation and Partnerships:

  • Launched several new products, including a helium-free 3T MRI and AI-enabled solutions.
  • Expanded partnerships with major U.S. health systems, enhancing market presence.

3. Forward Guidance and Outlook

• 2026 Expectations:
  • Anticipated comparable sales growth of 3% to 4.5%, with all business segments contributing.
  • Adjusted EBITDA margin expected to improve to 12.5% to 13%.
  • Free cash flow projected between EUR 1.3 billion and EUR 1.5 billion.
  • Continued focus on productivity with a new EUR 1.5 billion productivity program set for 2026-2028.

4. Bad News, Challenges, or Points of Concern

• Tariff Impact: Anticipated net impact of EUR 250 million to EUR 300 million from tariffs in 2026, despite mitigation efforts.
• China Market Caution: While expecting stabilization, there are concerns regarding tender activities and competition affecting growth in the region.
• Precision Diagnosis Segment: Flat performance in Q4 raised questions about momentum going into 2026, especially given the higher exposure to China.

5. Notable Q&A Insights

• Order Intake Dynamics: Management highlighted strong order intake momentum, particularly in North America, but acknowledged longer conversion cycles in D&T compared to Connected Care.
• Margin Improvement Factors: Management emphasized that gross margin improvements would continue despite tariff impacts, driven by innovation and productivity.
• China Market Outlook: Differentiated outlook between Personal Health and D&T, with cautious optimism for Personal Health but concerns about the health systems segment.
• Q1 2026 Guidance: Expected to start at the lower end of the growth range due to seasonality and tariff impacts, with a balanced growth profile anticipated throughout the year.

This summary encapsulates the key financial metrics, strategic initiatives, and outlook for Philips while addressing challenges and insights from the Q&A session.